Salim Syed

Stock Analyst at Mizuho

(1.92)
# 3,072
Out of 4,893 analysts
81
Total ratings
36.92%
Success rate
-8.02%
Average return

Stocks Rated by Salim Syed

Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16$14
Current: $1.80
Upside: +677.78%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103$84
Current: $36.59
Upside: +129.57%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207$169
Current: $135.33
Upside: +24.88%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235$280
Current: $300.37
Upside: -6.78%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100$117
Current: $114.54
Upside: +2.15%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19$22
Current: $7.95
Upside: +176.73%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113$163
Current: $36.26
Upside: +349.53%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25$18
Current: $9.54
Upside: +88.78%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.75
Upside: +49.45%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82$99
Current: $59.00
Upside: +67.80%
Maintains: Buy
Price Target: $60$53
Current: $46.27
Upside: +14.55%
Maintains: Buy
Price Target: $12$6
Current: $0.10
Upside: +5,840.59%
Maintains: Buy
Price Target: $28$21
Current: $0.87
Upside: +2,321.59%
Maintains: Buy
Price Target: $168$36
Current: $18.35
Upside: +96.19%